Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 15/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912120 | 0.97 | ABCG2 (0.94) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL13912108 | 0.96 | ABCG2 (0.92) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL3712664 | 0.92 | ABCG2 (1.00) | ABCG2ABCB1LMNA | |
| SCHEMBL13882455 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL13882342 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL23876088 | 0.92 | ABCG2 (1.00) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL13912111 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL13912124 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL13912118 | 0.92 | ABCG2 (0.84) | ABCG2ABCB1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL13912132 | 0.89 | ABCG2 (1.00) | ABCG2ABCB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| EP-2214485-B1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | ABCG2 1889/4885ABCB1 510/4885LMNA 2016/4885 |
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | ABCG2 1889/4885ABCB1 510/4885LMNA 2016/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | ABCG2 1889/4885ABCB1 510/4885LMNA 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.